NEWS
Novel modular spectral flow cytometry system
Beckman Coulter Life Sciences has launched a modular spectral flow cytometry system, the CytoFLEX mosaic Spectral Detection Module, which the company says is an industry first. When connected to the CytoFLEX LX or S Flow Cytometers, the CytoFLEX mosaic Spectral Detection Module delivers superior fluorescence sensitivity for dim and complex multicolour experiments and can detect nanoparticles as small as 80 nm. It uniquely provides two unmixing algorithms and up to 10 autofluorescence channels, with up to 88 detection channels. The richer data resulting from spectral analysis can help untangle the complexities of biological systems and diseases faster, with a nuanced understanding of immune cell subsets, their functions and interactions, thanks to simultaneously detecting multiple markers. In contrast to conventional flow
cytometry, spectral flow cytometry acquires the full emission spectrum of each antibody-associated fluorophore across all lasers, rather than measuring only the peak of emission. This powerful evolution delivers a more detailed and precise characterisation of cellular properties to advance understanding of complex biological systems and diseases within each sample versus legacy approaches. The CytoFLEX mosaic spectral detection module is powered by a unique algorithm capable of improving resolution compared to other available methods, along with unmixing accuracy checks to ensure efficiency. CytExpert software for spectral reduces the need for extensive training. Additionally, the module comes with tools to ease the full spectral workflow, with access to the FluoroFinder panel builder and a Cytobank premium license to provide all the tools researchers need to go from sample preparation to analysis of complex spectral data in an easy manner.
Register now for the BSMT 40th Anniversary Conference
Registration is now open for the British Society for Microbial Technology (BSMT) Microbiology Conference, taking place at the RAF Museum in Hendon, North London, on 15 May. The conference will host a range of speakers from different fields of microbiology including those in academia, research and clinical practice. An early bird delegate registration price of £50 is available until 28 April (£70 thereafter), included in which is morning coffee, light refreshments and lunch. A full- time student rate of £30 is also available. As well as the scientific programme, the day will also feature a trade exhibition featuring 20 leading microbiology companies. The scientific programme is entitled ‘Laboratory Microbial Diagnostics: Current and Future Practice’ and will feature the following presentations: n Biomarker-guided antibiotic treatment for patients with sepsis: providing value for patients and services? Professor Paul Dark, National Deputy Medical Director, NIHR Clinical Research Network,
University of Manchester.
n Novel technologies and the fight against antimicrobial resistance. Professor Hermine Mkrtchyan, Head of Research, University of West London.
n The Mini-Lab: accessible clinical bacteriology at the district level. Dr Alessandra Natale, MSF Paris.
n Developing the UK public health rapid support team Rapid Response Mobile Laboratory as a tool for global outbreak response. Dr Daniel Carter, Genomics Specialist, UKHSA Porton Down.
n Wastewater surveillance for epidemiological surveillance. Dr Alexander Shaw, Imperial College, London.
n Advances in the diagnosis of invasive/ systemic fungal infections. Dr Riina Richardson, Honorary Consultant Mycologist and Senior Clinical Lecturer in Infectious Diseases and Medical Education, Manchester.
Register for your place at the BSMT website –
www.bsmt.org.uk.
Novel LDT to assess liver fibrosis
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of its first laboratory developed test (LDT) FibroSIGHT.
This marks a significant
milestone for the company as it enters clinical care for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH). MASH has long been a challenging and progressive liver disease, characterised by fat build-up and inflammation that, if left untreated, leads to fibrosis and, ultimately, cirrhosis. As treatment options expand, accurate fibrosis assessment becomes even more critical in guiding clinical decisions and optimising patient outcomes. HistoIndex has been playing a key role in the development of MASH treatments and is now leading the way in this next phase of patient care with FibroSIGHT, with the test now available in the US. FibroSIGHT integrates into routine clinical workflows, leveraging HistoIndex’s proprietary stain-free imaging technology to enhance the sensitivity of fibrillar
12
collagens detection – key in evaluating fibrosis severity in liver biopsy samples. The illustration above compares FibroSIGHT’s Second Harmonic Generation Versus Masson’s Trichrome Staining, demonstrating FibroSIGHT’s detection of fine collagen fibres with exceptional clarity and an excellent signal-to-noise ratio. By eliminating variability associated with traditional staining techniques, FibroSIGHT delivers reliable and precise fibrosis assessment for MASH patients. “I am excited to see how our core expertise in clinical trial assessments is now transcending into the realm of precise and personalised patient care,” said Dr Gideon Ho, Chief Executive Officer of HistoIndex.” With FibroSIGHT, we aim to empower clinicians with a more definitive and accurate assessment of liver fibrosis.”
APRIL 2025
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
